Abstract
Amyloid-PET detects fibrillar β-amyloid deposits, a defining feature of Alzheimer’s disease. This technology has been used in research for over 20 years, and is now used in clinical practice to guide patient diagnosis and management. However, the real-world use of amyloid-PET may differ from research settings due to less standardized acquisition protocols, less experienced visual readers, and patients with more comorbidities, potentially compromising test accuracy. We evaluated the performance of amyloid-PET as used in a real-world clinical setting utilizing data collected via the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study.
The study collected clinical amyloid-PET scans of older adults with cognitive decline acquired in 294 imaging facilities using three FDA-approved radiotracers. We centrally processed these scans using a PET-only processing pipeline and derived summary quantification of cerebral radiotracer retention measured on the Centiloid scale. We applied an a priori autopsy-based threshold of 24.4 Centiloids to quantitatively define scan positivity and compared this quantitative classification with binary visual reads performed by local radiologists or nuclear medicine physicians.
10,350/10,774 scans (96%) passed quality control and were successfully quantified. Median patient age was 75 (interquartile range 71, 80) years, 51% were females, 87% self-identified as White, 63% had mild cognitive impairment (vs. 37% with dementia), and 61% of scans were visually positive based on local reads. Centiloid values were higher in visually positive scans (median=74 [46, 99]) compared to scans locally read as negative (−2 [−13, 12]; p<0.001). Patients with dementia had higher Centiloids than those with mild cognitive impairment (57 [8, 91] vs. 34 [−2, 79]; p<0.001), consistent with a higher visual positivity rate (70% vs. 56%, respectively; p<0.001). Agreement between local visual reads and quantitative classification was 86.3% (95%CI: 85.7%, 87.0%), corresponding to Cohen’s Kappa of 0.715 (95%CI: 0.701, 0.729; p<0.001). Overall, 5,519 [53% of total] scans were positive by both visual read and quantification (V+/Q+); 3,416 [33%] were negative by both (V-/Q-), 813 [8%] were V+/Q-, and 602 [6%] were V-/Q+. Female sex, White race, and use of the radiotracers 18F-flutemetamol and 18F-florbetaben (compared to 18F-florbetapir) were associated with higher visual-quantitative concordance.
In conclusion, local visual reads showed high concordance with central quantification of clinical amyloid-PET scans, supporting the validity of amyloid-PET as used in the real world and the use of quantification in clinical settings.
Competing Interest Statement
DS serves as a member on the Alzheimer's Association International Research Grant Program Council. CW received honorarium from the American Academy of Neurology, Kinetix Group, Onviv, LCN, and funding from NIH and the Alzheimer's association. BAS received grants to institution from ACR during the conduct of the study; personal fees from Avid Radiopharmaceuticals, Curium Pharma, Progenics Pharmaceuticals, Lantheus Medical Imaging, American Medical Foundation, Siemens Healthineers (for spouse), ACR (also for spouse), Capella Imaging, Eastern Cooperative Oncology Group and the ACR Imaging Network Medical Research Foundation (also for spouse), Evicore Healthcare (for spouse), GE Healthcare, Merrimack Pharmaceuticals, and Radiological Society of North America (also for spouse) outside the submitted work; and grants from Curium Pharma, Progenics Pharmaceuticals, ImaginAb, and Blue Earth Diagnostics outside the submitted work. LI is currently a full-time employee of Eli Lilly and Company / Avid Radiopharmaceuticals and a minor shareholder of Eli Lilly and Company; His contribution to the work presented in this manuscript was performed while he was affiliated with the University of California, San Francisco. GDR receives research support from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, Genentech; and served as a paid consultant for Alector, C2N, Eli Lilly, Johnson & Johnson, Roche, and Merck; He is a member of the AD Therapeutics Workgroup and an Associate Editor for JAMA Neurology. RLJ served as a paid consultant for GE Healthcare; he is an associate Editor for Alzheimer's Research and Therapy. No other competing interests were reported.
Funding Statement
The quantification of IDEAS Amyloid-beta-PET scans was funded by the Alzheimer's Association. IDEAS was funded by the Alzheimer's Association, the ACR, Avid Radiopharmaceuticals Inc (a wholly owned subsidiary of Eli Lilly and Company), GE Healthcare, and Life Molecular Imaging. DSM was supported by NIH/NIA grant K23AG076960. GDR and RLJ were supported by NIH/NIA grants P30-AG062422 and R35 AG072362. The funders/sponsors had no role in the current analysis or the drafting and the decision to submit the manuscript for publication. The funders/sponsors had a role in the design and conduct of IDEAS and in the collection, management, analysis, and interpretation of IDEAS data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In short, the study was managed by the American College of Radiology (ACR) under a central institutional review board (IRB) (Advarra, formerly Schulman Associates), with some sites requiring local IRB approval. Written informed consent for patient participation was obtained by the dementia specialist (see below), either directly from the patient or, in instances in which the specialist determined that the patient lacked the capacity to consent, from a legally authorized representative with patient assent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data presented in this manuscript (clinical, demographic, and imaging variables, including CL values) are available through the Global Alzheimer’s Association Interactive Network (https://www.gaaindata.org/partner/IDEAS). Raw and processed PET images are also available through the IDA at Laboratory of Neuro Imaging (https://ida.loni.usc.edu/login).
